@prefix rdf: . @prefix ns1: . @prefix ns2: . ns1:DB00799 rdf:type ns2:Drug ; ns2:description "Tazarotene (marketed as Tazorac\u00AE, Avage\u00AE and Zorac\u00AE) is a prescription topical retinoid sold as a cream or gel. This medication is approved for treatment of psoriasis, acne, and sun damaged skin (photodamage). [Wikipedia]"@en ; ns2:dosage , , , , , , , , , ; ns2:group "approved"@en , "investigational"@en ; ns2:halfLife "The half-life of the active form of the drug, tazarotenic acid, is approximately 18 hours in normal and psoriatic patients."@en ; ns2:indication "Used to treat psoriasis, acne and sun damaged skin (photodamage)."@en ; ns2:manufacturer . @prefix owl: . @prefix ns4: . ns1:DB00799 owl:sameAs ns4:DB00799 . @prefix ns5: . ns1:DB00799 owl:sameAs ns5:DB00799 . @prefix dcterms: . ns1:DB00799 dcterms:title "Tazarotene"@en . @prefix adms: . @prefix ns8: . ns1:DB00799 adms:identifier ns8:PA164746821 . @prefix ns9: . ns1:DB00799 adms:identifier ns9:Tazarotene , . @prefix ns10: . ns1:DB00799 adms:identifier ns10:DB00799 , . @prefix ns11: . ns1:DB00799 adms:identifier ns11:D01132 , . @prefix ns12: . ns1:DB00799 adms:identifier ns12:C12531 , , ; ns2:mechanismOfAction "Although the exact mechanism of tazarotene action is not known, studies have shown that the active form of the drug (tazarotenic acid) binds to all three members of the retinoic acid receptor (RAR) family: RARa, RARb, and RARg, but shows relative selectivity for RARb, and RARg and may modify gene expression. It also has affinity for RXR receptors."@en ; ns2:packager , ; ns2:patent , , ; ns2:routeOfElimination "Tazarotene and tazarotenic acid were metabolized to sulfoxides, sulfones and other polar metabolites which were eliminated through urinary and fecal pathways."@en ; ns2:synonym "Tazarotenum"@en , "Zorac"@en , "Tazarotene"@en , "Tazorac"@en , "Tazaroteno"@en , "Avage"@en ; ns2:toxicity "Excessive topical use may lead to marked redness, peeling, or discomfort. Oral ingestion of the drug may affect liver function causing hypertriglyceridemia. Other symptoms may include conjunctival irritation, hair loss, headache, edema, fatigue, dermatitis, nausea, and visual disturbances. Oral administration of this material to rats and rabbits at doses of 0.20 mg/kg/day (rabbits) and 0.25 mg/kg/day (rats) resulted in developmental toxicity. A no effect level of 0.05 mg/kg/day was established. Similar teratogenic effects have been reported for other retinoid compounds."@en . @prefix ns13: . ns1:DB00799 ns13:hasAHFSCode ; ns2:proteinBinding "The active form of the drug, tazarotenic acid, is highly bound to plasma proteins (>99%)."@en ; ns2:synthesisReference "Samuele Frigoli, Claudio Fuganti, Stefano Serra, Francesco Pizzocaro, Angelo Bedeschi, Paolo Tubertini, \"Process for the preparation of Tazarotene.\" U.S. Patent US20060205950, issued September 14, 2006."@en . @prefix foaf: . ns1:DB00799 foaf:page , , ; ns2:IUPAC-Name ; ns2:InChI ; ns2:Molecular-Formula ; ns2:Molecular-Weight ; ns2:Monoisotopic-Weight ; ns2:SMILES ; ns2:Water-Solubility , ; ns2:logP , , ; ns2:logS . @prefix ns15: . ns1:DB00799 ns13:hasATCCode ns15:D05AX05 ; ns2:H-Bond-Acceptor-Count ; ns2:H-Bond-Donor-Count ; ns2:InChIKey ; ns2:Polar-Surface-Area--PSA- ; ns2:Polarizability ; ns2:Refractivity ; ns2:Rotatable-Bond-Count ; ns2:absorption "Minimal systemic absorption of tazarotene occurs due to its rapid metabolism in the skin to the active metabolite, tazarotenic acid, which can be systemically absorbed and further metabolized. Gender had no influence on the systemic bioavailability of tazarotenic acid."@en ; ns2:affectedOrganism "Humans and other mammals"@en ; ns2:casRegistryNumber "118292-40-3"@en ; ns2:category " "@en ; ns2:containedIn , , , , , , , , , , , ; ns2:Bioavailability ; ns2:Ghose-Filter ; ns2:MDDR-Like-Rule ; ns2:Number-of-Rings ; ns2:Physiological-Charge ; ns2:Rule-of-Five ; ns2:Traditional-IUPAC-Name ; ns2:pKa--strongest-basic- .